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CERTIFICATES OF CONFIDENTIALITY: MIND THE GAP
Leslie E. Wolf* and Laura M. Beskow**
I. INTRODUCTION
Certificates of Confidentiality (“Certificates”) are a federal mechanism
designed to protect sensitive, identifiable research data from compelled disclosure
in any legal proceeding. The 21st Century Cures Act revised the authorizing statute
to address criticisms raised about the Certificates’ coverage and protections. Despite
many changes that expanded the scope and reinforced the protection of Certificates,
questions remain concerning the robustness of the protection Certificates afford.
Here, we briefly review the legal evolution of Certificates and then examine the gaps
in protections that remain and their implications. We conclude with
recommendations for areas of clarification and future research.
II. THE EVOLUTION OF CERTIFICATES
Certificates are a tool to help researchers meet their ethical and legal obligations
to protect research participants’ privacy and the confidentiality of their data.1
Authorized by federal law and granted by units of the U.S. Department of Health
and Human Services (HHS), Certificates are intended to prevent—with limited
exceptions—the disclosure of identifiable information about research participants
during any legal proceeding.2
*
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Geddes Stahlman Chair in Medical Ethics in the Center for Biomedical Ethics & Society at
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official views of NHGRI or NIH. The authors would like to thank Saliha Moore, a J.D.
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1
See generally Leslie E. Wolf, Mayank J. Patel, Brett A. Williams Tarver, Jeffrey L.
Austin, Lauren A. Dame & Laura M. Beskow, Certificates of Confidentiality: Protecting
Human Subject Research Data in Law and Practice, 43 J.L. MED. & ETHICS 594 (2015)
(discussing the confidentiality protections provided by Certificates of Confidentiality).
2
42 U.S.C. § 241(d) (2018); see also Leslie E. Wolf, Mayank J. Patel, Brett A.
Williams & Jeffery L. Austin, Certificates of Confidentiality: Protecting Human Subject
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The purpose of providing this protection is to facilitate important public health
research on sensitive topics. Originally authorized in 1970 for research on illegal
drug use, the impetus for Certificates was concern about people’s willingness to
participate in research if disclosure of identifiable data could place them in legal
jeopardy or have other adverse consequences for their financial standing,
employability, insurability, or reputation.3
Over time, the applicability of Certificates has been expanded from “research
on the use and effect of drugs”4 to a broader set of research topics. The most recent
amendments to the statutory language governing Certificates came with the
enactment of the 21st Century Cures Act.5 Certificates now apply to “biomedical,
behavioral, clinical, or other research in which identifiable, sensitive information is
collected (including research on mental health and on the use and effect of alcohol
and other psychoactive drugs).”6
The 21st Century Cures Act also implemented other significant substantive and
procedural changes to Certificates, including:
•

Mandatory issue: Previously, researchers were required to apply for a
Certificate and issuance was at the discretion of the HHS Secretary.7 Under
current statute, the Secretary “shall” issue a Certificate if the research is
funded (in whole or part) by the federal government.8 Indeed, the National
Institutes of Health (NIH) considers a Certificate automatically issued for

Research Data in Law and Practice, 14 MINN. J.L. SCI. & TECH. 11, 20–26 (2013)
(presenting a comprehensive history of Certificates of Confidentiality) [hereinafter Wolf et
al., Certificates of Confidentiality]. For a discussion of changes made to the Certificate of
Confidentiality through the 21st Century Cures Act, see generally Leslie E. Wolf & Laura
M. Beskow, New and Improved? 21st Century Cures Act Revisions to Certificates of
Confidentiality, 44 AM. J.L. & MED. 343 (2018) [hereinafter Wolf & Beskow, New and
Improved?].
3
Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513,
§§ 3(a), 303(a), 84 Stat. 1236, 1241 (codified at 42 U.S.C. § 242a(a) (1970)) (current version
at 42 U.S.C. § 241(d) (2018)). For a discussion of the history of the Comprehensive Drug
Abuse Prevention and Control Act, see Wolf et al., Certificates of Confidentiality, supra note
2, 20–25.
4
Pub. L. No. 91-513, sec. 3(a), § 303(a), 84 Stat. 1236, 1241 (codified at
42 U.S.C. § 242a(a) (1970)).
5
Wolf et al., Certificates of Confidentiality, supra note 2, at 20–25; 21st Century Cures
Act, Pub. L. 114-255, sec. 2012, § 301, 130 Stat. 1033, 1049–50 (2016)); see also Kathy L.
Hudson & Francis S. Collins, The 21st Century Cures Act—A View from the NIH, 376 NEW
ENG. J. MEDICINE 111, 112 (2017) (describing key features of the 21st Century Cures Act);
Wolf & Beskow, New and Improved?, supra note 2 (describing the key changes to the
Certificate authorizing statute and its implications).
6
42 U.S.C. § 241(d)(1)(A) (2018).
7
42 U.S.C. § 241(5)(d) (2015).
8
42 U.S.C. § 241(d)(1)(A)(i) (2018).
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all research it funds that involve identifiable, sensitive information.9
Obtaining a Certificate for research not funded by the federal government
still requires application and approval.10
Scope: Certificate holders were previously authorized to withhold the
“names or other identifying characteristics” of research participants.11 That
scope has now been expanded to authorize the withholding of “the name
of such an individual or any such information, document, or biospecimen
that contains identifiable, sensitive information about such an individual
and that was created or compiled for purposes of the research.”12
Definition of identifiability: Previously defined primarily by reference to a
list of specific identifiers,13 the term “identifiable, sensitive information”
now means:
§ information (a) through which an individual is identified; or (b) for
which there is at least a very small risk, as determined by current
scientific practices or statistical methods, that some combination of
the information, a request for the information, and other available
data sources could be used to deduce the identity of an individual.14
Disclosure prohibition: Prior statutory language stated that Certificate
holders “may not” be compelled in any federal, state, or local civil,
criminal, administrative, legislative, or other proceedings to identify
research participants.15 The current statute more forcefully asserts that
Certificate holders “shall not” make such disclosures.16 The statute goes on
to provide that:

9
NIH, NOT-OD-17-109, NOTICE OF CHANGES TO NIH POLICY FOR ISSUING
CERTIFICATES OF CONFIDENTIALITY (2017) [hereinafter NIH, NOTICE OF CHANGES TO NIH
POLICY].
10
42 U.S.C. § 241(d)(1)(A)(ii) (2018).
11
Id. § 241(d).
12
Id. § 241(d)(1)(D).
13
42 C.F.R. § 2a.2(g) (2009) (defining “identifying characteristics” as “the name,
address, any identifying number, fingerprints, voiceprints, photographs or any other item or
combination of data about a research subject which could reasonably lead directly or
indirectly by reference to other information to identification of that research subject”).
14
42 U.S.C. § 241(d)(4) (2018); see also Frequently Asked Questions (FAQs)
Certificates of Confidentiality, NIH, at A.6 (Apr. 28, 2020) https://grants.nih.gov/faqs#/cert
ificates-of-confidentiality.htm?anchor=question55502
[https://perma.cc/G4LN-333D]
[hereinafter Certificates of Confidentiality FAQ].
15
42 U.S.C. § 241(d) (2018).
16
Id. § 241(d)(1)(D) (“Any person to whom a certificate is issued under subparagraph
(A) to protect the privacy of an individual described in such subparagraph shall not, in any
Federal, State, or local, civil, criminal, administrative, legislative, or other proceeding,
disclose or provide the name of such individual or any such information, document, or
biospecimen that contains identifiable, sensitive information about the individual and that
was created or compiled for purposes of the research, except in the circumstance described
in subparagraph (C)(iii).”).
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identifiable, sensitive information shall be immune from the legal
process, and shall not, without the consent of the individual to
whom the information pertains, be admissible as evidence or used
for any purpose in any legal proceeding;17 and
identifiable, sensitive information collected by a person to whom a
Certificate has been issued, and all copies thereof, shall be subject
to the protections afforded for perpetuity.18

These prohibitions against disclosure are subject to limited exceptions—
allowing only for disclosures that are required by federal, state, or local laws
(excluding instances of legal demands); necessary for the medical treatment of the
individual to whom the information pertains; made with the consent of the individual
to whom the information pertains; or made for the purposes of other scientific
research that is in compliance with applicable federal regulations governing the
protection of human subjects in research.19
As we have discussed in detail elsewhere, the changes made to the Certificate
authorizing statute through the 21st Century Cures Act addressed several key
concerns about Certificates.20 While there are many positive aspects of these
changes,21 two new provisions reveal gaps in the Certificates’ protections. First, the
protection of “all copies . . . for perpetuity” faces practical challenges created by the
inclusion of research data in the Electronic Health Record (EHR).22 Second, the
permitted disclosure of information as “required by Federal, State, and local laws”
(excluding instances of compelled disclosure)23 may be broader than currently
described—and raises important questions about whether recommended consent
language adequately informs research participants about the scope of the permitted
disclosures. In the next section, we explore these gaps and their implications.

17
Id. § 241(d)(1)(E) (“Identifiable, sensitive information protected under subparagraph
(A), and all copies thereof, shall be immune from the legal process, and shall not, without
the consent of the individual to whom the information pertains, be admissible as evidence or
used for any purpose in any action, suit, or other judicial, legislative, or administrative
proceeding.”).
18
Id. § 241(d)(1)(F) (“Identifiable, sensitive information collected by a person to whom
a certificate has been issued under subparagraph (A), and all copies thereof, shall be subject
to the protections afforded by this section for perpetuity.”).
19
Id. § 241(d)(1)(C).
20
See generally Wolf & Beskow, New and Improved?, supra note 2.
21
Id.
22
42 U.S.C. § 241(d)(1)(F) (2018).
23
Id. § 241(d)(1)(C)(i); id. § 241(d)(1)(D).
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III. GAPS IN PROTECTION FROM DISCLOSURE
A. All Copies in Perpetuity: Research Data in Electronic Health Records
Integration of clinical and research data is increasingly viewed as desirable for
advancing the goals of both healthcare and research.24 For example, access to such
data could allow clinicians to avoid drug interactions or facilitate an appropriate
response to an adverse health event. Some studies routinely put research data in
EHRs.25 The most prominent example of routine inclusion of research data in health
records is the Veterans Affairs Hospitals, which have policies requiring the creation
24
See, e.g., Overhaul of the Human Research Subject Common Rule Proposed, MED.
DEVICES REP. ¶ 21,295, 2015 WL 7510317, 7 (2018) (“Clinical research networks connected
through electronic health records (EHRs) have developed methods for extracting clinical
data for research purposes and are working toward integration of research data into EHRs in
a meaningful way. . . . Recent trends clearly show that the scientific community recognizes
the value of data sharing and open-source resources and understands that pooling intellectual
resources and capitalizing on efficient uses of data and technology represent the best ways
to advance knowledge.”); Philipp Bruland, Justin Doods, Tobias Brix, Martin Dugas &
Michael Storck, Connecting Healthcare and Clinical Research: Workflow Optimizations
Through Seamless Integration of EHR, Pseudonymization Services and EDC Systems, 119
INT’L J. MED. INFORMATICS 103 (2018) (describing an approach to integrate electronic health
records and research data); see also James Scheibner, Marcello Ienca, Sotiria Kechagia, Juan
Ramon Troncoso-Pastoriza, Jean Louis Raisaro, Jean-Pierre Hubaux, Jacques Fellay & Effy
Vayena, Data Protection and Ethics Requirements for Multisite Research with Health Data:
A Comparative Examination of Legislative Governance Frameworks and the Role of Data
Protection Technologies, 7 J.L. & BIOSCIENCES 1, 5 (2020) (noting that Australia has high
rates of electronic health record systems and research data linkage).
25
See, e.g., Iftikhar J. Kullo, Ra’ad Haddad, Cynthia A. Prows, Ingrid Holm, Saskia C.
Sanderson, Nanibaa’ A. Garrison, Richard R. Sharp, Maureen E. Smith, Helena Kuivaniemi,
Erwin P. Bottinger, John J. Connolly, Brendan J. Keating, Catherine A. McCarty, Marc S.
Williams & Gail P. Jarvik, Return of Results in the Genomic Medicine Projects of the
eMERGE Network, 5 FRONTIERS GENETICS 1, 2 (2014) (“pharmacogenomic information is
being placed preemptively in the EHR as part of the network-wide eMERGE PGx project”);
Omri Gottesman, Helena Kuivaniemi, Gerard Tromp, W. Andrew Faucett, Rongling Li, A.
Manolio, Saskia C. Sanderson, Joseph Kannry, Randi Zinberg, Melissa A. Basford, Murray
Brilliant, David J. Carey, Rex L. Chisholm, Christopher G. Chute, John J. Connolly, David
Crosslin, Joshua C. Denny, Carlos J. Gallego, Jonathan L. Haines, Hakon Hakonarson, John
Harley, Gail P. Jarvik, Isaac Kohane, Iftikhar J. Kulio, Eric B. Larson, Catherine McCarty,
Marylyn D. Ritchie, Dan M. Roden, Maureen E. Smith, Erin P. Bottinger, Marc S. Williams
& The eMERGE Network, The Electronic Medical Records and Genomics (eMERGE)
Network: Past, Present, and Future, 15 GENETICS MEDICINE 761 (2013) (“These data [pulled
from EHRs] can then be combined with genomic data for the discovery of genotypephenotype associations, and the discoveries, once validated, may be introduced back into the
[EMR] to augment clinical care.” (emphasis added)); see also Anya E.R. Prince, John M.
Conley, Arlene M. Davis, Gabriel Lazaro-Munoz & R. Jean Cadigan, Automatic Placement
of Genomic Research Results in Medical Records: Do Researchers Have a Duty? Should
Participants Have a Choice?, 43 J.L. MED. & ETHICS 827, 827–32 (2015).
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of a health record for research participants who receive research interventions on an
inpatient or outpatient basis; the U.S. Department of Veterans Affairs has required
this practice since at least 2015.26
The 21st Century Cures Act’s express extension of Certificate protections to all
copies of the research information suggests that research data placed in the medical
record remains protected from compelled disclosure. As the NIH explains in its
frequently asked questions about Certificates:
Section 301(d) of the Public Health Services Act protects identifiable,
sensitive information and all copies thereof. Accordingly, if identifiable,
sensitive information protected by a Certificate is placed in a subject’s
medical record, the protections of the Certificate and prohibitions on
further disclosure of the information may apply.27
The most significant concern about the robustness of protection for copies of
Certificate-protected information in the EHR results from the combination of two
factors: (1) information contained in EHRs is subject to subpoena28 and (2) large
numbers and types of individuals and entities within and outside the health system
have legitimate access to EHRs without a legal demand.29 A third-party could
26

U.S. DEP’T OF VETERANS AFFS., VHA DIRECTIVE 1907.01, HEALTH INFORMATION
MANAGEMENT AND HEALTH RECORDS (Mar. 19, 2015). Section 23.g provides that “[a] VA
health record must be created or updated for all research subjects when required by VHA
research policy as found in VHA Handbook 1200.05.” Section 23.h further provides that “[a]
method to identify clinic visits solely for research must be used to differentiate those visits
from any other clinic visits.” Id.; see also U.S. DEP’T OF VETERANS AFFS., VHA DIRECTIVE
1200.05(2), REQUIREMENTS FOR THE PROTECTION OF HUMAN SUBJECTS IN RESEARCH (Jan.
7, 2019). Section 5.g specifies that “[e]ach VA investigator is responsible for: . . . (16)
[c]reating or updating a VHA health record and creating a progress note for all research
subjects (Veterans or non-Veterans) who receive research procedures or interventions as
inpatients or outpatients at VA medical facilities that are either used in or may impact the
medical care of the research subject at a VA medical facility or at facilities contracted by VA
to provide services to Veterans (e.g., Community-Based Outpatient Clinics or community
living centers).”
27
Certificates of Confidentiality FAQ, supra note 14, at A.12 (emphasis added).
28
The Health Information Portability & Accountability Act (HIPAA) Privacy Rule,
which sets a federal floor for the protection of identifiable health information, has multiple
exceptions to its protections, including pursuant to a court order or subpoena. While some
state laws provide more protection than HIPAA does, these similarly typically allow for
disclosure pursuant to a court order or subpoena. See discussion in Leslie E. Wolf, Erin Fuse
Brown, Ryan Kerr, Genevieve Razick, Gregory Tanner, Brett Duvall, Sakinah Jones, Jack
Brackney & Tatiana Posada, The Web of Legal Protections for Participants in Genomic
Research, 29 HEALTH MATRIX 1, 43–47, 77–88 (2019) [hereinafter Wolf et al., The Web of
Legal Protections].
29
Under HIPAA and related state medical privacy laws, covered entities and business
associates typically can access protected health information for treatment, payment, and
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potentially access information covered by a Certificate by serving a subpoena on
any of these individuals or entities, who may be—or most likely are—unaware of
the Certificate. Our prior research revealed that even people in the research context
who were aware of Certificates were often unfamiliar with the details of their
protections.30 We have noted that this lack of familiarity could lead to unauthorized
disclosure of Certificate-protected information should research data be subpoenaed
directly from researchers.31 This risk may be magnified by NIH’s shift to automatic
issue of Certificates.32 Accordingly, it is hard to imagine that individuals who are
not involved in research and, thus, do not have any exposure to Certificates, would
know to treat the research data in the EHR differently from the rest of the EHR if
they received a subpoena and to avoid disclosure as the new provisions intend.
Even if the recipient of the subpoena understands to withhold the Certificatecovered research information in the EHR, it will be up to the institution to defend
against legal efforts to compel disclosure. NIH provides limited assistance, if any,
to institutions that receive a legal demand for data protected by a Certificate.33
Institutions may not be willing to take on the legal costs of resisting disclosure
health care operations. Id. at 43–47. The following categories of people fall within this
authorized disclosure: treating physician(s), consulting physician(s), nurse(s), physician
assistants, technicians, pharmacist, appointments personnel, billing personnel, quality
assurance personnel, state licensure personnel, accreditation personnel, and insurers.
Disclosures can also be made without authorization for law enforcement, public health or
other governmental purposes. Id.
30
Leslie E. Wolf, Lauren A. Dame, Mayank J. Patel, Brett A. Williams, Jeffrey A.
Austin & Laura M. Beskow, Certificates of Confidentiality: Legal Counsels’ Experiences
with and Perspectives on Legal Demands for Research Data, 7 J. EMPIRICAL RSCH. HUM.
RSCH. ETHICS 1, 6 (2012) [hereinafter Wolf et al., Counsels’ Experiences and Perspectives]
(finding “counsel [who represent academic medical centers] are not particularly
knowledgeable about Certificates’ protections and exceptions”); Laura M. Beskow, Devon
K. Check, Emily E. Namey, Lauren A. Dame, Li Lin, Alexandra Cooper, Kevin P. Weinfurt
& Leslie E. Wolf, Institutional Review Boards’ Use and Understanding of Certificates of
Confidentiality, 7 PLOS ONE 1, 3 (2012) (finding “only slightly more than half (55%) of
respondents answered three or more of the six knowledge questions correctly”).
31
This problem is heightened with data sharing between research teams because
researchers receiving the data may be unaware that the data come with the Certificates’
protections. Wolf & Beskow, New and Improved?, supra note 2, at 349.
32
42 U.S.C. § 241(d)(1)(A)(i) (2018); NIH, NOTICE OF CHANGES TO NIH POLICY,
supra note 9.
33
Laura M. Beskow, Lauren Dame & E. Jane Costello, Certificates of Confidentiality
and Compelled Disclosure of Data, 322 SCIENCE 1054, 1055 (2008) [hereinafter
Beskow et al., Compelled Disclosure of Data]; Wolf et al., Counsels’ Experiences and
Perspectives, supra note 30, at 7. The NIH Certificate kiosk previously included a statement
that the “NIH Legal Advisor is willing to discuss the regulations with the researcher’s
attorney[,]” although some institutional counsel desired more proactive assistance. Id. at 9.
Now, the FAQ only indicates that a “researcher should immediately seek legal counsel from
his or her institution” should they receive legal action seeking release of personally
identifying information protected by a Certificate. Certificates of Confidentiality FAQ, supra
note 14, at F.2.
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should the case end up in court.34 With the strengthening of the statute’s provisions
from the permissive “may not” to the mandatory “shall not disclose,”35 institutions
should undertake such fights, but they may not do so if they do not fully appreciate
the protections afforded the data.
Further, the extension of Certificate protections to research data in the EHR
undermines a strategy that legal counsel have used to avoid challenges to a
Certificate’s protections. In our interviews with them, institutional legal counsel told
us that, when they received a subpoena for research data protected by a Certificate,
they would consider whether there were other sources for the data the requester
sought. Often the information sought was originally collected independently for
medical purposes. Accordingly, counsel would suggest to the requestor that they
subpoena the medical record. This approach allowed them to avoid a court fight that
might end in a decision that formally limits Certificate protections.36 If research
information is in the EHR, this avenue is foreclosed; institutional legal counsel will
still be called on to withhold the research data in the EHR and may have to defend
those denials of disclosure and risk judgments adverse to Certificate protections.
B. Disclosure Permitted as Required by Federal, State, and Local Law
The revised Certificate statute eliminates researchers’ voluntary disclosure of
identifiable data protected by a Certificate,37 but explicitly authorizes disclosure
otherwise protected by the Certificate when “required by Federal, State, or local
laws.”38 In public presentations and in suggested consent language, NIH has referred
only to disclosures pursuant to traditional public health reporting, such as
communicable diseases, abuse, and harm to self or others.39 However, the language
of this provision is unbounded, and our prior research revealed myriad state laws
that may apply to various types of research.40 Accordingly, the scope of the
34

Beskow et al., Compelled Disclosure of Data, supra note 33, at 1055. We have heard
of cases in which institutions have turned over data over researchers’ objections, but we have
been unable to confirm these anecdotal accounts (which also would not appear in reported
cases).
35
See supra notes 15–16 and accompanying text; 42 U.S.C. § 241(d) (2018); id.
§ 241(d)(1)(D).
36
Wolf et al., Counsels’ Experiences and Perspectives, supra note 30, at 6.
37
See supra notes 15–16 and accompanying text.
38
42 U.S.C. § 241(d)(1)(C)(i); see also Wolf & Beskow, New and Improved?, supra
note 2, at 350.
39
The sample consent language released after the statutory changes referred to child
abuse and communicable diseases. Suggested Consent Language Describing the CoC
Protections, NIH (Dec. 11, 2017) [https://perma.cc/2JSL-M5HS]. The current version refers
to “child or elder abuse, some communicable diseases, and threats to harm yourself or
others.” Example Informed Consent Language, NIH (May 23, 2019),
https://grants.nih.gov/policy/humansubjects/coc/helpful-resources/suggested-consent.htm
[https://perma.cc/MA6C-YMSW] [hereinafter Example Informed Consent Language].
40
Wolf et al., The Web of Legal Protections, supra note 28.
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disclosures that may be made under this provision may be much broader than NIH’s
sample consent language suggests.
While a comprehensive analysis requires significant legal research, we provide
three examples that illustrate the potential breath of this exception.
Our first two examples fit within the kinds of laws that the NIH sample consent
language highlights, but they may not be ones that come to mind when reading the
statement: “The Certificate DOES NOT stop reporting that federal, state or local
laws require. Some examples are laws that require reporting of child or elder abuse,
some communicable diseases, and threats to harm yourself of others.”41 Imagine a
study seeking to identify safe and effective treatment of substance use disorder
among pregnant women. Many states require any person42 to report child abuse,
whereas others require only those who are in particular professions or hold a certain
license to do so.43 Some states also define child abuse or neglect to include the use
of a controlled substance during pregnancy and/or evidence of substance use after
delivery.44 Accordingly, researchers would be required to report substance abuse by
a pregnant research participant if the researchers were identified as a mandated
reporter and the state’s child abuse or neglect statute applies to the use of a controlled
substance during pregnancy and/or evidence of substance use after delivery. These
circumstances fit within the way NIH has described the intent of the provision
allowing for disclosure “as required by Federal, State, and local law”: disclosures
consistent with public health reporting requirements and “harm to self or others.”
However, it is unclear whether the typical research participant would understand that
substance use during pregnancy falls within these categories.
But the circumstances described above are exactly the type of studies for which
the Certificate was first intended. Certificates were adopted to facilitate research on

41

Example Informed Consent Language, supra note 39.
CHILD WELFARE INFO. GATEWAY, MANDATORY REPORTS OF CHILD ABUSE AND
NEGLECT 2 (Apr. 2019), childwelfare.gov/pubPDFs/manda.pdf [https://perma.cc/52RN5HJS] (identifying 18 states and Puerto Rico as requiring “any person who suspects child
abuse or neglect” to report); see, e.g., TEX. FAM. CODE ANN. § 261.101(a) (West 2019) (“A
person having cause to believe that a child’s physical or mental health or welfare has been
adversely affected by abuse or neglect by any person shall immediately make a report as
provided by this subchapter.”); TENN. CODE ANN. § 37-1-403 (2020) (“Any person who has
knowledge of or is called upon to render aid to any child who is suffering from or has
sustained any wound, injury, disability, or physical or mental condition shall report such
harm immediately if the harm is of such a nature as to reasonably indicate that it has been
caused by brutality, abuse or neglect or that, on the basis of available information, reasonably
appears to have been caused by brutality, abuse or neglect.”).
43
See, e.g., N.D. CENT. CODE § 50-25.1-03 (2019); 325 ILL. COMP. STAT. 5/4 (2020).
44
See, e.g., N.D. CENT. CODE § 50-25.1-17 (2019) (requires toxicology test and
reporting when reason to believe controlled substance use during pregnancy); TEX. FAM.
CODE ANN. § 261.001(1)(I) (2019) (child abuse definition includes use of controlled
substance “in a manner . . .that the use results in . . . injury to a child”); 705 ILL. COMP. STAT.
405/2–3(c) (2020) (child abuse definition includes the detection of any amount of a
controlled substance in a newborn).
42
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drug use.45 Researchers understood that people would be unlikely to participate in
this kind of research without strong confidentiality protections because disclosure
of their illegal drug use could put them in legal jeopardy.46 In our example, women
may be unwilling to participate—despite potential benefits to their and their babies’
health—without promises that they will not be reported to child protective services
or other authorities because of the very real risks of investigation, criminal process,
and loss of custody.47 These concerns could also impact studies that are not about
substance use per se, but include women who are pregnant or may become pregnant
and involve routine screening of blood samples. In such cases, it seems even less
likely that participants would understand the recommended consent language to
apply to their participation. As institutional legal counsel informed us, most legal
demands they received for disclosure were for information about individual
participants rather being related to the topic of the study.48 These legal demands arise
from “personal injury case[s] or divorce or custody matters in which the research
data might be relevant.”49
Similarly, researchers conducting studies that focus on cognitive or functional
impairment, as well as studies that routinely administer cognitive tests as only one
part of a broader focus, may be required to report conditions that may impair the
ability to drive safely. Some states require individuals with medical degrees to report
to the motor vehicle department certain conditions that may impair their ability to
drive.50 Others require physicians who diagnose a disorder “characterized by lapses
of consciousness” to report.51 In the latter group of states, physician-researchers
would have to report these conditions when identified in the course of research to
the government agency that oversees driving.52 The public health importance of such
reporting is clear, as are the risks to participants of such disclosure—including being
subject to investigation, loss of license, and the potential financial implications and
loss of independence that might result from loss of license to drive. But given the
limited statements about the types of mandated disclosures NIH has highlighted in
its model consent form language, it is not clear whether researchers appreciate that,
depending on the relevant state law, these are the kinds of exceptions to the
Certificate’s protections—and associated risks—that should be included in a consent
form.53
45

Wolf et al., Certificates of Confidentiality, supra note 2, at 20–24.
Id. at 18–25.
47
See Ferguson v. Charleston, 532 U.S. 67, 70–74 (2001) (discussing how a program
conducted by the Medical University of South Carolina resulted in pregnant women being
jailed as a result of drug use during pregnancy that was identified during a research study).
48
Wolf et al., Counsels’ Experiences and Perspectives, supra note 30, at 3.
49
Id. at 4.
50
See, e.g., OR. REV. STAT. § 807.710 (2020).
51
See, e.g., CAL. HEALTH & SAFETY CODE § 103900 (West 2020).
52
Id.
53
We previously highlighted that the gap created by the as “required by federal, state,
or local laws” provision creates problems for consent, noting “How do you describe what
46
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A review of the 21st Century Cures Act legislative history points to a third
example of disclosures that fall within the as “required by Federal, State or local
law” provision—state open records acts. Prior to the adoption of the 21st Century
Cures Act, there were concerns that genomic data that were “collected or retained
by a federal executive branch agency[ ] could be subject to public release pursuant
to the Freedom of Information Act (FOIA).”54 The 21st Century Cures Act
ultimately included language from the proposed, but unenacted, Advancing
Precision Medicine Act of 2016, to amend section 201 of the Public Health Service
Act to specifically exempt biomedical research information that is identifiable or
could be identifiable, if combined with other information, from disclosure under
FOIA.55 The language about identifiability of data is almost identical between the
amendments to FOIA and to the Certificate authorization; both provisions define
identified data as those that are explicitly identified or where “there is at least a very
small risk, as determined by current scientific practices or statistical methods, that
some combination of the information, a request for the information, and other
available data sources could be used to deduce the identity of an individual.”56
These changes bring such biomedical research data within one of the FOIA
exceptions to disclosure that might otherwise be required under the as “required by
Federal, State, or local law” provision.57 But, unless states similarly exempt research

this exception may include, if you do not know which laws may be implicated?” Wolf &
Beskow, New and Improved?, supra note 2, at 351.
54
C. STEPHEN REDHEAD ET AL., CONG. RSCH. SERV., R44502, SENATE MEDICAL
INNOVATION BILLS: OVERVIEW AND COMPARISON WITH THE 21ST CENTURY CURES ACT
(H.R. 6), 19 (May 17, 2016).
55
Advancing Precision Medicine Act of 2016, S. 2713, 114th Cong. § 4 (codified at 42
U.S.C. § 241(f) (2018)) (“The Secretary may exempt from disclosure under section 552(b)(3)
of title 5, United States Code, biomedical information that is about an individual and that is
gathered or used during the course of biomedical research if—(A) an individual is identified;
or (B) there is a risk, as determined by current scientific practices or statistical methods, that
some combination of the information, the request, and other available data sources could be
used to deduce the identity of an individual.” The 21st Century Cures Act adopts this
language with slight modifications. It omits the United States Code, and section (B) reads
“there is at least a very small risk, as determined by current scientific practices or statistical
methods, that some combination of the information, the request, and or other available data
sources could be used to deduce the identity of an individual.” (emphasis added)); 5 U.S.C.
§ 552(b)(3) (2016) (“This section [regarding public disclosure of information] does not apply
to matters that are—. . . (3) specifically exempted from disclosure by statute (other than
section 552b of this title), if that statute—(A)(i) requires that the matters be withheld from
the public in such a manner as to leave no discretion on the issue; or (ii) establishes particular
criteria for withholding or refers to particular types of matters to be withheld; and (B) if
enacted after the date of enactment of the OPEN FOIA Act of 2009, specifically cites to this
paragraph.”).
56
42 U.S.C. § 241(d)(1)(G)(4) (2018).
57
5 U.S.C. § 552(b)(3) (2016).
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records from disclosure,58 research data held by state entities may be subject to
disclosure under state open records laws.59 While a comprehensive review of these
statutes is beyond the scope of this article, some states explicitly include their public
universities and colleges within their open records laws.60 Provisions that exempt
research data may be drafted to focus on researcher benefit, rather than participant
protections, and may not protect against some disclosures (e.g., after publication of

58

See, e.g., WYO. STAT. ANN. § 16-4-203(b)(iii) (2020) (“The custodian may deny the
right of inspection of the following records, unless otherwise provide by law, on the ground
that disclosure to the applicant would be contrary to the public interest: . . . (iii) The specific
details of bona fide research projects being conducted by a governmental entity or any other
person.”).
59
A 2010 report of state open records laws notes the substantial variation in terms of
entities and records included in the scope of the laws and exemptions to the obligations to
disclose. NAT’L ASSOC. COUNTIES, OPEN RECORDS LAWS: A STATE BY STATE REPORT (Dec.
2010), https://www.governmentecmsolutions.com/files/124482256.pdf [https://perma.cc/T
XZ8-4UU4]. Alabama is an example of a broad statute with limited exceptions that do not
address research data. ALA. CODE § 36-12-40 (2020) (“Every citizen has the right to inspect
and take a copy of any public writing of this state, except as otherwise expressly provided
by statute. Provided however, registration and circulation records and information
concerning the use of the public, public school or college and university libraries of this state
shall be exempted from this section. Provided further, any parent of a minor child shall have
the right to inspect the registration and circulation records of any school or public library that
pertain to his or her child. Notwithstanding the foregoing, records concerning security plans,
procedures, assessments, measures, or systems, and any other records relating to, or having
an impact upon, the security or safety of persons, structures, facilities, or other
infrastructures, including without limitation information concerning critical infrastructure
(as defined at 42 U.S.C. § 5195c(e) (2001) as amended) and critical energy infrastructure
information (as defined at 18 C.F.R. § 388.113(c)(1) as amended) the public disclosure of
which could reasonably be expected to be detrimental to the public safety or welfare, and
records the disclosure of which would otherwise be detrimental to the best interests of the
public shall be exempted from this section. Any public officer who receives a request for
records that may appear to relate to critical infrastructure or critical energy infrastructure
information, shall notify the owner of such infrastructure in writing of the request and
provide the owner the opportunity to comment on the request and on the threats to public
safety or welfare that could reasonably be expected from public disclosure on the records.”).
60
See, e.g., 5 ILL. COMP. STAT. 140/2 (2020) (“(a) ‘Public body’ means all legislative,
executive, administrative, or advisory bodies of the State, state universities and colleges,
counties, townships, cities, villages, incorporated towns, school districts and all other
municipal corporations, boards, bureaus, committees, or commissions of this State, any
subsidiary bodies of any of the foregoing including but not limited to committees and
subcommittees thereof, and a School Finance Authority created under Article 1E of the
School Code. ‘Public body’ does not include a child death review team or the Illinois Child
Death Review Teams Executive Council established under the Child Death Review Team
Act, or a regional youth advisory board or the Statewide Youth Advisory Board established
under the Department of Children and Family Services Statewide Youth Advisory Board
Act.” (emphasis added) (footnotes omitted)). “Private information” is defined by specific
identifiers, without reference to the kinds of connections that may be made. Id. at (c-5).
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research findings).61 Again, as this example illustrates, current NIH sample consent
language may not sufficiently convey the kinds of exceptions to Certificate
protections that matter to prospective participants.
IV. RECOMMENDATIONS
Certificates have been an important tool for protecting the confidentiality of
research data for fifty years. The 21st Century Cures Act made important changes
to the Certificate statute that strengthened those protections. However, a closer look
at those changes reveals gaps that could undermine Certificate protections and
participant trust. We have outlined two of those here: the provision protecting all
copies of research data in perpetuity and the provision authorizing disclosure of
identifiable information as “required by Federal, State, and local law.”
Our concerns about the extension of Certificate protections to all copies in
perpetuity are about implementing that provision in practice. Our discussion focused
on the specific risk posed by placing research data in EHRs. Academic medical
centers and other health care institutions that are incorporating research data in
EHRs need to consider what strategies they can adopt to ensure they have met their
obligations under the Certificate. For example, they may develop systems that flag
protected research data before disclosure in response to a subpoena. Tailored
education for appropriate personnel might also reduce risk of inappropriate
disclosure of protected research data. NIH could aid the research community by

61

See, e.g., 5 ILL. COMP. STAT. 140/7 (2020) (exempting from disclosure “(i) Valuable
formulae, computer geographic systems, designs, drawings and research data obtained or
produced by any public body when disclosure could reasonably be expected to produce
private gain or public loss” and “(j) The following information pertaining to educational
matters: . . . (iv) course materials or research materials used by faculty members” (emphasis
added)); see also Georgia’s Open Records Law, which has exceptions for research records
but is framed in terms of researcher interests, rather than participant protection. GA. CODE
ANN. § 50-18-72 (2020) (providing exceptions for “(35) Data, records, or information of a
proprietary nature produced or collected by or for faculty or staff of state institutions of
higher learning, or other governmental agencies, in the conduct of, or as a result of, study or
research on commercial, scientific, technical, or scholarly issues, whether sponsored by the
institution alone or in conjunction with a governmental body or private concern, where such
data, records, or information has not been publicly released, published, copyrighted, or
patented; (36) Any data, records, or information developed, collected, or received by or on
behalf of faculty, staff, employees, or students of an institution of higher education or any
public or private entity supporting or participating in the activities of an institution of higher
education in the conduct of, or as a result of, study or research on medical, scientific,
technical, scholarly, or artistic issues, whether sponsored by the institution alone or in
conjunction with a governmental body or private entity, until such information is published,
patented, otherwise publicly disseminated, or released to an agency whereupon the request
must be made to the agency. This paragraph shall apply to, but shall not be limited to,
information provided by participants in research, research notes and data, discoveries,
research projects, methodologies, protocols, and creative works.”).
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developing education materials that address the general purposes of Certificates and
how they apply to research data in EHRs for institutions to use.
With respect to the provision authorizing disclosure as “required by Federal,
State, and local law,” we believe that elucidation of the full scope of this exception
is critically needed. As we have illustrated, important examples are not reflected in
the current consent language and there may be others. How much detail is important
to prospective participants is a matter for empirical inquiry. For example, it may be
sufficient to amend NIH’s recommended language to state: “Common examples are
laws that require reporting of child or elder abuse, some communicable diseases,
and threats to harm yourself or others. Your state may have others.” (amendments in
italics).62 However, research might demonstrate that additional specific exceptions
should be listed.
Some authorized disclosures, however, may be inconsistent with the
Certificate’s underlying purpose, and action may be required to close those gaps. As
we discuss, states’ open records laws demonstrate one way that research data
protected by a Certificate may be at risk of disclosure because of this new provision.
Given that FOIA was amended to protect research data from disclosure in the same
legislation that amended the Certificate’s statutory authority, it is illogical to think
the drafters intended to make research data protected by a Certificate vulnerable to
state open records laws. Without additional research, we cannot know the full scope
of the exceptions this provision has introduced, how best to respond, or how best to
inform participants.

62

Cf. Example Informed Consent Language, supra note 39.

